@article{MTMT:34757284,
	title = {Postoperative Bisphosphonates Use is Associated with Reduced Adverse Outcomes After Primary Total Joint Arthroplasty of Hip and Knee: A Nationwide Population-Based Cohort Study},
	url = {https://m2.mtmt.hu/api/publication/34757284},
	author = {Shih, Jen-Ta and Tan, Timothy L. and Shen, Pei-Hung and Yeh, Tsu-Te and Wu, Chia-Chun and Pan, Ru-Yu and Chien, Wu-Chien and Chung, Chi-Hsiang and Wang, Sheng-Hao},
	doi = {10.1007/s00223-024-01192-6},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {34757284},
	issn = {0171-967X},
	keywords = {revision surgery; BISPHOSPHONATES; periprosthetic joint infection; Total joint arthroplasty; periprosthetic fracture},
	year = {2024},
	eissn = {1432-0827}
}

@article{MTMT:34631367,
	title = {Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients},
	url = {https://m2.mtmt.hu/api/publication/34631367},
	author = {Bosman, A. and Appelman-Dijkstra, N. M. and Boot, A. M. and de Borst, M. H. and van de Ven, A. C. and de Jongh, R. T. and Bokenkamp, A. and van den Bergh, J. P. and van der Eerden, B. C. J. and Zillikens, M. C.},
	doi = {10.1007/s00223-023-01172-2},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {34631367},
	issn = {0171-967X},
	keywords = {Phosphate; hypophosphatemia; FGF23; X-linked hypophosphatemia; XLH},
	year = {2024},
	eissn = {1432-0827}
}

@article{MTMT:34790122,
	title = {Changes in Blood Pressure is Associated with Bone Loss in US Adults: A Cross-Sectional Study from NHANES 2005–2018},
	url = {https://m2.mtmt.hu/api/publication/34790122},
	author = {Liu, S. and Wu, S. and Bao, X. and Ji, J. and Ye, Y. and Guo, J. and Liu, J. and Wang, X. and Zhang, Y. and Hao, D. and Huang, D.},
	doi = {10.1007/s00223-023-01176-y},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	volume = {114},
	unique-id = {34790122},
	issn = {0171-967X},
	year = {2024},
	eissn = {1432-0827},
	pages = {276-285}
}

@article{MTMT:34374598,
	title = {Co-occurrence of Spondyloepiphyseal Dysplasia and X-Linked Hypophosphatemia in a Three-Generation Chinese Family},
	url = {https://m2.mtmt.hu/api/publication/34374598},
	author = {Ma, Jian and Zhang, Ye and Ding, Xiaoxiao and Liang, Zhijiang and Yang, Chaoxiang and Deng, Zhi and He, Hui and Guan, Zhihong and Zeng, Chunhua and Lin, Yunting and Luo, Xianqiong},
	doi = {10.1007/s00223-023-01104-0},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {34374598},
	issn = {0171-967X},
	abstract = {Rare genetic skeletal disorders (GSDs) remain the major problem in orthopedics and result in significant morbidity in patients, but the causes are highly diverse. Precise molecular diagnosis will benefit management and genetic counseling. This study aims to share the diagnostic experience on a three-generation Chinese family with co-occurrence of spondyloepiphyseal dysplasia (SED) and X-linked hypophosphatemia (XLH), and evaluate the therapeutic effects of two third-generation siblings. The proband, his younger brother, and mother presented with short stature, skeletal problems, and hypophosphatemia. His father, paternal grandfather, and aunt also manifested short stature and skeletal deformities. Whole exome sequencing (WES) of proband-brother-parents initially only found the proband and his younger brother had a pathogenic c.2833G > A(p.G945S) variant in the COL2A1 gene inherited from their father. Re-analysis of WES uncovered the proband and his younger brother also harbored a pathogenic ex.12 del variant in the PHEX gene transmitted from their mother. Sanger sequencing, agarose gel electrophoresis, and quantitative polymerase chain reaction proved these results. The proband and his younger brother were confirmed to have a paternally inherited SED and a maternally inherited XLH. During a 2.8-year follow-up, these two siblings remained short stature and hypophosphatemia, but their radiographic signs and serum bone alkaline phosphatase levels were improved with treatment of oral phosphate and calcitriol. Our study presents the first report of co-occurrence of SED and XLH, shows the possibility that two different rare GSDs co-exist in a single patient, and alerts clinicians and geneticists to be cautious about this condition. Our study also suggests that next-generation sequencing has limit in detecting exon-level large deletions.},
	keywords = {X-linked hypophosphatemia; PHEX gene; Genetic skeletal disorders; spondyloepiphyseal dysplasia},
	year = {2023},
	eissn = {1432-0827},
	orcid-numbers = {Zhang, Ye/0000-0002-2523-460X; Guan, Zhihong/0000-0002-2022-2765; Zeng, Chunhua/0000-0001-5954-1803; Lin, Yunting/0000-0001-8974-357X}
}

@article{MTMT:34237994,
	title = {Assessment of Bone Microarchitecture in Patients with Systemic Mastocytosis and its Association with Clinical and Biochemical Parameters of the Disease},
	url = {https://m2.mtmt.hu/api/publication/34237994},
	author = {Franco, Andre S. and Murai, Igor H. and Takayama, Liliam and Caparbo, Valeria F. and Marchi, Luan L. and Velloso, Elvira D. R. P. and Pereira, Rosa M. R.},
	doi = {10.1007/s00223-023-01107-x},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {34237994},
	issn = {0171-967X},
	abstract = {Patients with systemic mastocytosis (SM) are at high risk of bone deterioration. However, the evaluation of bone microarchitecture in this disease remains unclear. We aimed to assess bone microarchitecture in patients with SM. This was a cross-sectional study of 21 adult patients with SM conducted in a quaternary referral hospital in Sao Paulo, Brazil. A healthy, age-, weight-, and sex-matched cohort of 63 participants was used to provide reference values for bone microarchitecture, assessed by high resolution peripheral quantitative computed tomography (HR-pQCT). Total volumetric bone mineral density (vBMD), cortical vBMD, and cortical thickness at the radius were significantly lower in the control group compared with the SM group (all P < 0.001). Patients with aggressive SM had significantly lower trabecular number (Tb.N) (P = 0.035) and estimated failure load (F.load) (P = 0.032) at the tibia compared with those with indolent SM. Handgrip strength was significantly higher in patients who had more Tb.N at the radius (rho, 0.46; P = 0.036) and tibia (rho, 0.49; P = 0.002), and lower who had more trabecular separation at the radius (rho, -0.46; P = 0.035) and tibia (rho, -0.52; P = 0.016). Strong and positive associations between F.load (rho, 0.75; P < 0.001) and stiffness (rho, 0.70; P < 0.001) at the radius, and between F.load at the tibia (rho, 0.45; P = 0.038) were observed with handgrip strength. In this cross-sectional study, aggressive SM was more susceptible to bone deterioration compared with indolent SM. In addition, the findings demonstrated that handgrip strength was associated with bone microarchitecture and bone strength.},
	keywords = {Bone metabolism; Tryptase; HR-pQCT; handgrip; secondary osteoporosis},
	year = {2023},
	eissn = {1432-0827}
}

@article{MTMT:34089802,
	title = {Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy},
	url = {https://m2.mtmt.hu/api/publication/34089802},
	author = {Jayash, S.N. and Hamoudi, D. and Stephen, L.A. and Argaw, A. and Huesa, C. and Joseph, S. and Wong, S.C. and Frenette, J. and Farquharson, C.},
	doi = {10.1007/s00223-023-01116-w},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	volume = {online},
	unique-id = {34089802},
	issn = {0171-967X},
	year = {2023},
	eissn = {1432-0827},
	pages = {online}
}

@article{MTMT:33993336,
	title = {Messages from the Mineral: How Bone Cells Communicate with Other Tissues},
	url = {https://m2.mtmt.hu/api/publication/33993336},
	author = {Plotkin, Lilian I. and Sanz, Natasha and Brun, Lucas R.},
	doi = {10.1007/s00223-023-01091-2},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {33993336},
	issn = {0171-967X},
	abstract = {Bone is a highly dynamic tissue, and the constant actions of bone-forming and bone-resorbing cells are responsible for attaining peak bone mass, maintaining bone mass in the adults, and the subsequent bone loss with aging and menopause, as well as skeletal complications of diseases and drug side-effects. It is now accepted that the generation and activity of bone-forming osteoblasts and bone-resorbing osteoclasts is modulated by osteocytes, osteoblast-derived cells embedded in the bone matrix. The interaction among bone cells occurs through direct contact and via secreted molecules. In addition to the regulation of bone cell function, molecules released by these cells are also able to reach the circulation and have effects in other tissues and organs in healthy individuals. Moreover, bone cell products have also been associated with the establishment or progression of diseases, including cancer and muscle weakness. In this review, we will discuss the role of bone as an endocrine organ, and the effect of selected, osteoblast-, osteocyte-, and osteoclast-secreted molecules on other tissues.},
	keywords = {osteoblast; osteocyte; Osteoclast; Endocrine actions},
	year = {2023},
	eissn = {1432-0827}
}

@article{MTMT:33935465,
	title = {Extensive and Differential Deterioration of Hip Muscles May Preexist in Older Adults with Hip Fractures: Evidence from a Cross-Sectional Study},
	url = {https://m2.mtmt.hu/api/publication/33935465},
	author = {Ling, Ming and Huang, Hou and Li, Xianlong and Xu, Yueyang and Fan, Yongqian},
	doi = {10.1007/s00223-022-01043-2},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {33935465},
	issn = {0171-967X},
	abstract = {Hip muscles play an increasingly important role in lower limb function with aging. Investigating the deterioration of hip muscles and its relationship with hip fracture (HF) may help identify older adults prone to fall. In this study, patients with fall-related HF within 48 h and non-fracture controls aged >= 60 years were enrolled. The cross-sectional area (size) and attenuation (density) of the hip flexors, extensors, adductors, and abductors were calculated after segmentation on computed tomography images. The correlation of muscle parameters with HF and age were evaluated using logistic and multiple regression, respectively. Discrimination of HF was analyzed by receiver-operating characteristic analyses. A total of 220 patients and 91 controls were included. The size of the flexors, extensors, and abductors, and the density of the flexors, adductors, and abductors were lower in patients with HF after adjustment for sex, age, and body mass index (BMI). However, decreased muscle size was only observed in hip extensors in patients aged 60-74 years. Decreased muscle size was associated with HF independent of sex, age, BMI, and hip trabecular bone mineral density. Abductor size exhibited a significantly larger negative correlation with age in patients compared to controls. Including abductor size or all muscle size was effective for discrimination of HF in patients aged >= 75 years. In conclusion, older adults with HF may have sustained extensive and differential hip muscle deterioration before the injury; extensor atrophy in younger-old age and consideration of a closer relationship between abductor size and age deserve attention.},
	keywords = {MUSCLE; hip fracture; Sarcopenia; falls},
	year = {2023},
	eissn = {1432-0827}
}

@article{MTMT:33915164,
	title = {Nonresponder Considerations for Romosozumab Treatment},
	url = {https://m2.mtmt.hu/api/publication/33915164},
	author = {Tominaga, Ayako and Wada, Keiji and Okazaki, Ken and Nishi, Hideharu and Terayama, Yasushi and Shimamoto, Shuji and Kodama, Yasuteru and Kato, Yoshiharu},
	doi = {10.1007/s00223-023-01087-y},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {33915164},
	issn = {0171-967X},
	abstract = {Romosozumab can increase bone mineral density (BMD) in patients with osteoporosis, but some patients do not respond to it. This study aimed to identify risk factors for being a nonresponder to romosozumab treatment. This retrospective observational study included 92 patients. Romosozumab (210 mg) was subcutaneously administered to the participants every 4 weeks over 12 months. We excluded patients who previously underwent treatment for osteoporosis to assess the impact of romosozumab alone. We evaluated the proportion of patients who did not respond to romosozumab treatment to the lumbar spine and hip with increased BMD. Nonresponders were defined as those with a bone density change of < 3% after 12 months of treatment. We compared demographics and biochemical markers between responders and nonresponders. We found that 11.5% of patients were nonresponders at the lumbar spine, and 56.8% were nonresponders at the hip. A risk factor for nonresponse at the spine was low type I procollagen N-terminal propeptide (P1NP) values at 1 month. The cutoff value for P1NP at month 1 was 50 ng/ml. We found that 11.5% and 56.8% of patients experienced no significant improvement in the lumbar spine and hip BMD, respectively. Clinicians should use nonresponse risk factors to inform decisions about romosozumab treatment for patients with osteoporosis.},
	keywords = {osteoporosis; bone mineral density; ROMOSOZUMAB; Nonresponder},
	year = {2023},
	eissn = {1432-0827}
}

@article{MTMT:33869264,
	title = {The Clinical Effectiveness of Denosumab (Prolia (R)) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/33869264},
	author = {Moshi, Magdalena Ruth and Nicolopoulos, Konstance and Stringer, Danielle and Ma, Ning and Jenal, Mathias and Vreugdenburg, Thomas},
	doi = {10.1007/s00223-023-01078-z},
	journal-iso = {CALCIFIED TISSUE INT},
	journal = {CALCIFIED TISSUE INTERNATIONAL},
	unique-id = {33869264},
	issn = {0171-967X},
	abstract = {To assess the effectiveness and safety of denosumab (Prolia (R)) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW). Systematic searches were run in PubMed, Embase & Cochrane Library on 27-April-2022. Randomized controlled trials (RCTs) that included osteoporotic PMW allocated to denosumab, SERMs, bisphosphonates, or placebo were eligible for inclusion. RCTs were appraised using Cochrane Risk of Bias 2.0. Bayesian network and/or pairwise meta-analyses were conducted on predetermined outcomes (i.e. vertebral/nonvertebral fractures, bone mineral density [BMD], mortality, adverse events [AEs], serious AEs (SAEs), withdrawals due to AEs, AEs caused by denosumab discontinuation). A total of 12 RCTs (k = 22 publications; n = 25,879 participants) were included in the analyses. Denosumab, reported a statistically significant increase in lumbar spine (LS) and total hip (TH) BMD, compared to placebo. Similarly, denosumab also resulted in a statistically significant increase in TH BMD compared to the raloxifene and bazedoxifene. However, relative to denosumab, alendronate, ibandronate and risedronate resulted in significant improvements in both femoral neck (FN) and LS BMD. With regards to vertebral fractures and all safety outcomes, there were no statistically significant differences between denosumab and any of the comparator. Relative to placebo, denosumab was associated with significant benefits in both LS and TH BMD. Additionally, denosumab (compared to placebo) was not associated with reductions in vertebral and nonvertebral fractures. Finally, denosumab was not associated with improvement in safety outcomes, compared to placebo. These findings should be interpreted with caution as some analyses suffered from statistical imprecision.},
	keywords = {POSTMENOPAUSAL WOMEN; systematic review; BISPHOSPHONATES; denosumab; Selective Estrogen Receptor Modulators; network meta-analysis},
	year = {2023},
	eissn = {1432-0827},
	orcid-numbers = {Nicolopoulos, Konstance/0000-0001-8165-189X}
}